The major histocompatibility complex (MHC) on chromosome 6p is an established risk locus for ulcerative colitis (UC) and Crohn's disease (CD). We aimed to better define MHC association signals in UC and CD by combining data from dense singlenucleotide polymorphism (SNP) genotyping and from imputation of classical human leukocyte antigen (HLA) types, their constituent SNPs and corresponding amino acids in 562 UC, 611 CD and 1428 control subjects. Univariate and multivariate association analyses were performed, controlling for ancestry. In univariate analyses, absence of the rs9269955 C allele was strongly associated with risk for UC (P ¼ 2.67 Â 10 À13 ). rs9269955 is a SNP in the codon for amino acid position 11 of HLA-DRb1, located in the P6 pocket of the HLA-DR antigen binding cleft. This amino acid position was also the most significantly UC-associated amino acid in omnibus tests (P ¼ 2.68 Â 10 À13 ). Multivariate modeling identified rs9269955-C and 13 other variants in best predicting UC vs control status. In contrast, there was only suggestive association evidence between the MHC and CD. Taken together, these data demonstrate that variation at HLA-DRb1, amino acid 11 in the P6 pocket of the HLA-DR complex antigen binding cleft is a major determinant of chromosome 6p association with UC.
INTRODUCTION
The major histocompatibility complex (MHC) on chromosome 6p contains the highly polymorphic human leukocyte antigen (HLA) genes and other immunoregulatory genes. 1, 2 Genetic variants in the MHC have been associated with susceptibility for many infectious and immune-mediated diseases including the inflammatory bowel diseases (IBDs), ulcerative colitis (UC) and Crohn's disease (CD). 3, 4 Features of the MHC such as dense gene clustering with broad linkage disequilibrium, extensive polymorphism and heterogeneity among different populations have made localization of causal variants challenging. 2 HLA polymorphisms were the focus of attention in several IBD candidate gene association studies of relatively small sample size and meta-analyses of these studies found HLA associations in UC that were mostly different from those found in CD. 3 --5 Subsequently, linkage between IBD and the chromosome 6p IBD3 locus was found in genome-wide linkage scans. 6 --8 Recent genomewide association studies (GWAS) have confirmed the MHC as one of 47 UC loci and 71 CD loci with significant evidence for association (Po5 Â 10 À8 ). 9, 10 The most significant association signal in a recent meta-analysis of six GWAS that included 6687 UC cases and 19 718 controls of European ancestry was at a singlenucleotide polymorphism (SNP) in the MHC class II region (rs9268853, P ¼ 1.35 Â 10 À55 ). 10 In contrast, the most significant MHC association signal in a meta-analysis of six CD GWAS that included a similar combined sample size (6333 CD cases and 15 056 controls) was less significant than the UC signal and was located in the MHC class III region near the lymphotoxin A locus (rs1799964, P ¼ 3.98 Â 10 À11 ). 9, 10 Here, we explore the MHC association signal in the discovery stage of a new UC and CD GWAS with excellent coverage (410 000 SNPs) across the extended MHC. We used our MHC SNP data and an existing reference data set to impute classical HLA allele types, their constituent SNPs, and corresponding amino acids in our UC, CD and control samples. This allowed us to evaluate if the observed SNP associations in the MHC can be explained by variation specifically in the classical HLA genes.
RESULTS

Analysis of genotyped MHC SNPs in IBD
First, we tested 10 347 genotyped SNPs in the MHC region from 29 299 to 33 884 kilobases (kb) on chromosome 6 using National Center for Biotechnology Information (NCBI)36/hg18 coordinates for association with UC and CD with ileal involvement. Among 35 SNPs that reached genome-wide significance (Po5 Â 10 À8 ) in the UC analysis, the most significant SNP was rs2647025 (odds ratio (OR) ¼ 1.95, 95% confidence interval (CI) ¼ (1.62 --2.35) for the G allele; P ¼ 1.94 Â 10 À12 ), located in the promoter region of HLA-DQB1 ( Figure 1a ). This SNP is correlated with rs9268853 (r 2 ¼ 0.63 in HapMap 3-CEU 11 ), which was the MHC region SNP with the most significant association in a recent UC GWAS meta-analysis, 10 and it is also correlated with rs2395185 (r 2 ¼ 0.60 in our data set), which was the MHC region SNP with the most significant association in the NIDDK IBD Genetics Consortium UC GWAS, 12 both at distances of 4200 kb.
In contrast, there was only suggestive evidence for association between MHC region SNPs and CD with ileal involvement ( Figure 2 ). The most significant association signal was found at rs17880124 (OR ¼ 2.23, 95% CI ¼ (1.52 --3.27) for the G allele; P ¼ 3.82 Â 10 À5 ), which is located in an exon of the MHC class I polypeptide-related sequence A gene. Of note, the association observed in UC was many orders of magnitude stronger than that in CD with ileal involvement despite a similar number of cases. Therefore, we focused on the UC signal through imputation of classical HLA alleles and their corresponding nucleotide and amino acid sequences.
Analysis of imputed classical HLA alleles in UC
The following imputed genetic markers were included in our UC vs control analyses: 156 classical HLA alleles at four-digit resolution, 95 classical HLA allele groups at two-digit resolution, 1765 binary SNP features at 1573 nucleotide positions and 561 binary HLA amino acid features at 357 amino acid positions. The most significant association signal in UC mapped to rs9269955 (Figure 1b ), which is a tri-allelic SNP within the coding region of HLA-DRB1 (position 32 660 116 using NCBI36/hg18 coordinates). In combination with the nucleotide position directly adjacent to it (rs17878703 at position 32 660 115), rs9269955 determines the codon for amino acid position 11 of the HLA-DRb1 protein, where six different amino acid alleles are observed in the population at large ( Table 1 ). Chromosome 6 position 32 660 114 is the third position in this codon, and it is not known to be polymorphic. rs9269955-C (to indicate the presence of the C allele) is associated with protection against UC (OR ¼ 0.51, 95% CI ¼ (0.43 --0.61), P ¼ 2.67 Â 10 À13 ). In combination with the adjacent rs17878703 alleles, rs9269955-C encodes three of the six observed amino acids (aspartic acid, valine or glycine) at HLA-DRb1 amino acid 11 (Table 1 ). This SNP is correlated with rs2395185 (r 2 ¼ 0.88 in our data set), which was the MHC region SNP with the most significant association in the NIDDK IBD Genetics Consortium UC GWAS. 12 To analyze the role of specific amino acid positions in the HLA genes in UC, we conducted omnibus tests for association with degrees-of-freedom equal to the number of distinct residues for that amino acid position minus one ( Table 2 ). The most significant finding was for HLA-DRb1 amino acid 11 (P ¼ 2.68 Â 10 À13 ), consistent with the results noted above ( Figure 1c ). Several other amino acid associations were highly significant including other amino acid positions in HLA-DRb1, HLA-DQa1 or HLA-DQb1 ( Table 2) .
As these results highlighted HLA-DRb1 amino acid 11, we further analyzed the six amino acids at this position and the corresponding classical HLA-DRB1 allele groups at two-digit resolution ( Table 3 ). The three amino acids (aspartic acid, valine and glycine) encoded by the rs9269955-C allele in combination with the adjacent rs17878703 alleles, are all associated with protection against development of UC.
Among 28 imputed classical HLA-DRB1 alleles tested at fourdigit resolution, three were significantly associated with UC (DRB1*15:01, OR¼ 1.59, 95% CI ¼ (1.31 --1.93), P ¼ 3.68 Â 10 À6 ; DRB1*01:03, OR ¼ 38.39, 95% CI ¼ (7.50 --196.60), P ¼ 1.20 Â 10 À5 ; DRB1*07:01, OR ¼ 0.61, 95% CI ¼ (0.48 --0.77), P ¼ 3.38 Â 10 À5 ).
As the above findings highlighted HLA-DRB1 association in UC, we then evaluated the quality of our classical HLA-DRB1 allele imputation at two-digit resolution by performing HLA-DRB1 genotyping via sequence-specific oligonucleotide probes and also next-generation sequencing using genomic DNA from 384 of our study subjects. This analysis demonstrated that the imputation procedure we applied was 98.8% accurate (see Supplementary  Materials) .
We next determined the most parsimonious model to explain the association of HLA-DRb1 amino acid 11 with UC using forward stepwise model selection for the six observed amino acids. The best model included only three of the six amino acids: valine, glycine and aspartic acid ( Table 3 ). The overall P-value for this best model was 3.60 Â 10 À13 as compared with a P-value of 2.68 Â 10 À13 for the full model that included all six amino acid alleles, suggesting that most of the association signal for UC at this position can be accounted for by only these three amino acids. Of note, valine, glycine and aspartic acid are the same three amino acids encoded by the most significant SNP allele, rs9269955-C, when it is combined with the adjacent rs17878703 SNP alleles. This provides good internal validation between these different analytic approaches and highlights that variation at HLA-DRb1 amino acid 11 explains much of the HLA association with UC.
UC vs control best multivariate model When we performed analyses conditioned on including either rs9269955-C or the HLA-DRb1 amino acid 11 variants, there were residual UC vs control association signals because of effects of other variants in the HLA region. This finding is consistent with prior observations in UC that multiple independent association signals exist in the MHC. We used a forward stepwise model selection procedure to select the best set of markers to predict UC (Table 4 ). This best model has an overall P-value of 4.28 Â 10 À40 and includes rs9269955-C and 13 other markers that span the chromosome 6 region from 29.45 to 33.81 megabases (Mb).
UC vs CD with ileal involvement best multivariate model
In order to compare HLA associations between UC and CD with ileal involvement, we performed an analysis using UC subjects as cases and CD with ileal involvement subjects as controls. Initial association analyses for all markers in our study were performed and then we applied stepwise model selection to determine the best model for a UC vs CD with ileal involvement comparison (Table 5a ). The model that was selected included 11 markers and had an overall model P-value of 4.48 Â 10 À33 . Not unexpectedly, there was no overlap between these markers and those that were chosen in the UC vs control best model described above (Table 4) .
We then used the 11 markers from the UC vs CD with ileal involvement best model to perform two further analyses: UC vs control and CD with ileal involvement vs control (Tables 5b and c) . The model P-value for UC vs control was 1.59 Â 10 À19 , which is Amino acid positions with omnibus Po5 Â 10 À8 are shown.
HLA-DRb1 amino acid 11 and ulcerative colitis J-P Achkar et al Abbreviations: Asp, aspartic acid; CI, confidence interval; Gly, glycine; HLA, human leukocyte antigen; Leu, leucine; OR, odds ratio; Pro, proline; Ser, serine; UC, ulcerative colitis; Val, valine. a All HLA-DRB1*11 alleles are associated with serine at HLA-DRb1 amino acid position 11, except HLA-DRB1*11:22
and HLA-DRB1*11:30, which are associated with valine and leucine, respectively. The multivariate best model for HLA-DRb1 amino acid 11 residues alone was identified with stepwise regression. Abbreviations: A1, allele 1; A2, allele 2; A, adenine; C, cytosine; CI, confidence interval; G, guanine; MHC, major histocompatibility complex; OR, odds ratio; T, thymine. Markers are listed according to the order in which they came into the model. The frequencies and ORs are given for the A1 allele. For markers with more than two alleles, presence or absence of the specified allele was compared. The reference sequence gene is listed for intragenic markers and the two flanking reference sequence genes are listed for intergenic markers. Full gene names corresponding to each gene symbol used in the 'Gene' column can be looked up on the Human Gene Nomenclature Committee web site (http://www.genenames.org/). less significant than the P-value of 4.28 Â 10 À40 for the unrestricted UC best model ( Table 4 ). The model P-value for CD with ileal involvement vs control was 1.42 Â 10 À5 . Divergent effects for each UC vs CD with ileal involvement best model marker in the UC vs control compared with the CD with ileal involvement vs control analyses are apparent when the ORs for each marker are compared.
DISCUSSION
The MHC locus demonstrates the strongest evidence for association to UC among 47 well-established UC loci identified in a GWAS meta-analysis, 10 and is also one of 71 well-established CD loci identified by GWAS meta-analysis. 9 In order to better understand MHC association signals in UC and CD, we used dense MHC SNP data from the discovery stage of an ongoing, new UC and CD GWAS to impute classical HLA types, their constituent SNPs and corresponding amino acids, and we performed detailed analyses of the genotyped and imputed data. Our univariate tests of binary SNP and SNP allele markers, and our omnibus tests of polymorphic HLA amino acid positions both highlighted HLA-DRb1, amino acid position 11 as the MHC feature most significantly associated with UC. The C allele of rs9269955 was the SNP allele most significantly associated with UC (presence of rs9269955-C is associated with protection and absence is associated with risk for UC). In combination with the immediately adjacent SNP, it encodes the valine, glycine or aspartic acid amino acid residues at HLA-DRb1, amino acid 11, which were all associated with protection against UC. Furthermore, in multivariate analysis, the most parsimonious model to explain the association with UC at amino acid 11 consisted of valine, glycine and aspartic acid as the only terms.
HLA-DRB1 has extensive polymorphism as demonstrated by its 928 alleles and the 704 proteins for which it codes (International Immunogenetics Information System/HLA Database: http:// www.ebi.ac.uk/imgt/hla). 13 Valine at amino acid 11 corresponds to the common DRB1*04 (DR4) or lower frequency DRB1*10 (DR10) allele groups, glycine to DRB1*07 (DR7) and aspartic acid to DRB1*09 (DR9). The HLA-DR4, -DR7 and -DR9 allele groups were associated with protection against UC in a meta-analysis of prior studies. 3 They almost always occur on haplotypes carrying the HLA-DRB4 gene, which encodes the DR53 antigen, and HLA-DRB4*01:01 has been associated with protection against UC in Japan. 14 In addition, the previously reported HLA-DR2 association with risk for UC 3,5 is consistent with our observation that proline at position 11 in HLA-DRb1 is associated with risk for UC. Based on the complementary findings from our different analyses and their correlation with results from prior studies, we conclude that variation at amino acid position 11 of HLA-DRb1 is a major determinant of chromosome 6p association with UC.
The potential biological significance of the UC association of amino acid position 11 relates to the peptide binding specificity of HLA class II molecules and their role in antigen presentation to T cells. 15, 16 The three-dimensional structure of the class II molecule HLA-DR1 heterodimer (DRA/DRB1*0101) has been well characterized and its peptide binding groove has been shown to be determined by polymorphic molecules that form nine pockets with different chemical and size characteristics. 15, 17 In one of these pockets (P6), amino acid position 11 appears to be the only variable residue and thus determines the binding specificity of that pocket. 18 Of note, hydrophobic amino acid residues at DRb1 amino acid 11 were found to be associated with protection against development of sarcoidosis. 19 This finding suggests that such hydrophobic interactions could affect peptide binding in the P6 pocket. 19 We therefore hypothesize that variation at the amino acid position 11 of HLA-DRb1 could have an effect on peptide binding in the HLA-DR complex antigen binding cleft that alters risk for the development of UC.
It is important to note that the MHC association signal in UC is complex and not completely explained by amino acid position 11 in HLA-DRb1. In fact, our forward stepwise model selection identified 13 other terms besides rs9269955-C. This model is highly significant with an overall P-value of 4.28 Â 10 À40 , but it will need to be validated in additional large cohorts. Included in our model was another missense SNP allele in HLA-DRB1, the T allele of rs1136759. rs1136759 and two adjacent flanking SNPs encode variation at HLA-DRb1, amino acid 13, which is located in the P4 pocket of the HLA-DR complex antigen binding cleft. The finding that two of the terms in the best model for prediction of UC risk relate to the HLA-DRb1 complex antigen binding cleft emphasizes the probable importance of HLA-DRB1 in the pathogenesis of UC. Four other MHC class II loci variants, including SNPs in HLA-DQB1 (rs1130380-C) and HLA-DRA (rs3135391), between HLA-DQA1 and HLA-DQB1 (rs9273363), and between HLA-DQA2 and HLA-DQB2 (rs6933763), were associated with UC in our multivariate model. The HLA-DRB, -DQB and -DPB genes are all highly polymorphic and encode b-chains of the class II molecule ab heterodimer while the a-chains are encoded by the HLA-DQA, -DPA genes and -DRA genes. 4 Three polymorphisms in MHC class III loci (rs440454, rs28435656 and rs915654) were included as terms in our UC vs control model. The MHC class III region is one of the most gene dense regions in the human genome. Two of the SNPs in our model, rs440454 and rs28435656, are in linkage disequilibrium (r 2 ¼ 0.54 in HapMap 3-CEU 11 ) and located in an MHC class III segment that contains four genes within 30 kb including superkiller viralicidic activity 2like and RD RNA-binding protein. 20 rs440454 is in perfect linkage disequilibrium (r 2 ¼ 1.0 in HapMap 3-CEU 11 ) with SNP rs419788 that was associated with risk for lupus. 21 rs28435656 is located in the complement component 2 gene, which is located immediately adjacent to the region that includes superkiller viralicidic activity 2-like and RD RNA-binding protein. Finally, rs915654 is located 5 prime to the lymphotoxin A locus, which has been associated with CD and diabetes. 22 All these findings suggest a role for MHC class III genes in UC pathogenesis, which warrants further investigation.
Another association of potential pathogenic interest identified in our UC vs control model is rs2844677, a synonymous SNP in the coding region of the mucin 21, cell surface associated (MUC21) gene. MUC21 is a recently identified gene that is expressed in normal colon among other tissues and produces a transmembrane mucin involved in cell adhesion. 23, 24 In the last part of our analysis, we compared MHC region association signals between UC and CD with ileal involvement. The finding that the 11 studied markers each had ORs with effects in opposite directions for the two IBD phenotypes together with the results from our initial association analysis in which the most significant associations in UC were different than those for ileal CD, demonstrates that the association signals for UC and ileal CD are quite different. This conclusion correlates with results of prior studies, which have shown that the only consistent associations with risk for both UC and CD have been for HLA-DRB1*01:03 and HLA-B52. 3, 4 In contrast, alleles of the HLA-DR2 split antigen DR15 have been associated in opposite directions with HLA-DRB1*15:01 associated with protection against CD and HLA-DRB1*15:02 associated with increased risk for UC. 3, 5 In summary, we have performed detailed analyses to better understand MHC association signals in UC and CD. Our most significant finding is that a specific variation at amino acid position 11 of HLA-DRb1, the only variable amino acid in the P6 pocket of the HLA-DR complex antigen binding cleft, explains a substantial portion of the MHC association signal and corresponds with several previously established classical HLA class II associations in UC. The observed alteration at amino acid position 11 of HLA-DRb1 may affect peptide binding and result in an altered immune activation underlying protection against UC. We have also developed a novel multivariate model that further defines the Abbreviations: A, adenine; A1, allele 1; A2, allele 2; C, cytosine; CI, confidence interval; G, guanine; HLA, human leukocyte antigen; ileal CD, Crohn's disease with ileal involvement; OR, odds ratio; T, thymine; UC, ulcerative colitis; Y, tyrosine. Markers are listed according to the order in which they came into the model. The frequencies and ORs are given for the A1 allele. For markers with more than two alleles, presence or absence of the specified allele was compared. The reference sequence gene is listed for intragenic markers and the two flanking reference sequence genes are listed for intergenic markers. Full gene names corresponding to each gene symbol used in the 'Gene' column can be looked up on the Human Gene Nomenclature Committee web site (http://www.genenames.org/). contribution of MHC variation to risk for UC and highlights other genes of potential importance in UC pathogenesis. Finally, our multivariate modeling suggests different effects of MHC polymorphisms in UC and CD.
SUBJECTS AND METHODS
Study subjects
Our study sample included 574 UC, 630 CD with at least ileal involvement and 1508 control subjects of European ancestry that were recruited for genetic studies at the Cleveland Clinic or the University of Pittsburgh under institutional review board-approved protocols. All subjects provided written informed consent. IBD diagnoses and assessment of disease location were confirmed by IBD physicians via review of primary medical records using standard endoscopic, radiographic and histologic criteria. These quality control steps were performed using the PLINK software. 25 Subsequently, tag SNPs with genotype missing rates o0.1% and physical separation of at least 0.4 Mb were used in spectral analysis of ancestry that identified 929 controls with a relatively homogenous 'European' ancestral background. Additional SNPs with minor allele frequencies o0.005 or Hardy --Weinberg Po0.001 in these 929 controls were removed from the data set.
Genotyping and quality control
Ancestry matching
To control for potential confounding because of variation in genetic ancestry, study subjects were grouped into 11 approximately homogenous clusters, based on genetic distances derived from GemTools. 26, 27 Ancestry was inferred based on SNPs with genotype missing rates o0.1% and a physical separation of at least 0.2 Mb. In all of the association analyses, we controlled for ancestry by including cluster membership as a blocking variable. The inflation across the genome-wide SNP data was minimal (genomic control lambda 28 ¼ 1.02 for UC vs control and 1.03 for CD with ileal involvement vs control), confirming that the samples were well matched.
Imputation of classical HLA, SNP and amino acid allele dosages
We followed a previously described procedure 29 to impute classical HLA alleles and their corresponding amino acid sequences in our cases and controls, using the genotyped SNPs in our GWAS as input. This imputation procedure is conceptually similar to HLA*IMP 32 in that haplotype information across the region is used to predict classical HLA alleles based on genotyped SNPs. A prior study demonstrated empirical evidence that the imputations have good accuracy 29 reaching comparable levels of accuracy to the work on which HLA*IMP is based. 32 As the reference panel, we used a data set of 263 HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1 and -DPB1 classical alleles at four-digit resolution, 3852 SNPs, and 372 amino acid positions in 2767 unrelated founder individuals of European descent collected by the MHC Working Group of the Type 1 Diabetes Genetics Consortium. 30 All variants were encoded as biallelic markers, allowing us to use standard tools for imputation. For variants with greater than two alleles, each allele was coded as present or absent, and analyzed in a separate test. We used default parameters for BEAGLE (http://faculty.washington.edu/browning/beagle/beagle.html): 10 iterations of phasing/imputation, testing four pairs of haplotype pairs for each individual at each iteration. For each variant, we used the posterior probabilities of carrying 0 (AA), 1 (AB) or 2 (BB) copies to calculate the effective dosage for allele B ( ¼ 2 Â Pr(BB) þ Pr(AB)). To obtain allele dosages for MHC region HumanOmni1-Quad SNPs, we used BEAGLE-CALL. 31 Three iterations of BEAGLECALL were run, with increasing stringency of genotype calling filters (callthreshold ¼ 0.9 and missingcohort ¼ 0.1 in iteration 1, callthreshold ¼ 0.98 and missingcohort ¼ 0.02 in iteration 2, and callthreshold ¼ 0.985 and missingcohort ¼ 0.015 in iteration 3). We combined dosage information for markers in the Type 1 Diabetes Genetics Consortium reference panel with dosage information for additional HumanOmni1-Quad SNPs that appeared in both genome builds NCBI36/hg18 and GRCh37/hg19 into a combined set of genetic features in the MHC region from 29 299 to 33 884 kb on chromosome 6 using NCBI36/ hg18 coordinates.
HLA-DRB1 imputation quality at two-digit resolution was assessed by sequence-specific oligonucleotide probes and next-generation sequencing of genomic DNA collected from 384 of our study subjects (see Supplementary Materials).
Association analyses
Association analyses were performed using allele dosage data from 562 UC, 611 CD with ileal involvement and 1428 control samples that passed quality control. We examined the association between binary markers in the HLA region and UC vs control and CD with ileal involvement vs control using logistic regression with a log-additive model. Forward stepwise model selection was used to determine a set of markers in the post imputation data that jointly predicted disease vs control status, without including multiple markers that were in tight linkage disequilibrium. Markers with an allele frequency o0.001 were excluded. The Bayesian Information Criterion was used to find a model that balanced model complexity with parsimony. The stepwise procedure started by taking the best marker (lowest P-value) into the regression model and iteratively adding markers until the Bayesian Information Criterion ceased to improve. This procedure was performed in R (http://www.r-project.org) using the 'glm' and 'step' functions.
For each polymorphic amino acid position in the HLA region, we also conducted an omnibus test for association using multivariate logistic regression with degrees-of-freedom equal to the number of distinct residues for that amino acid position minus one. For the position yielding the smallest P-value, we used stepwise regression, limited to that position, to select a parsimonious model for the site.
Finally, using stepwise regression we determined a model for differentiating UC and CD with ileal involvement. In this model, CD with ileal involvement subjects served as controls and UC subjects served as cases.
For each multivariate model, we provide the P-value associated with the best model. This P-value pertains to the null hypothesis that none of the terms in the model has any explanatory value, vs the alternative hypothesis that at least one term is associated with the phenotype. The degrees-of-freedom associated with this test equals the number of markers in the multivariate model.
